Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Tata Motors and Iveco Group Come Together to Build for the Future Creating a New Global Force in Commercial Mobility
-
Tata Motors and Iveco Group Come Together to Build for the Future Creating a New Global Force in Commercial Mobility
-
Form 8.5 (EPT/RI)-SThree Plc
-
New CCUA report shows how credit unions can help close the affordable housing financing gap—and keep housing affordable
-
Bilibili Inc. to Report Third Quarter 2026 Financial Results on Tuesday, November 24, 2026
-
Cerro de Pasco Resources Advances Comprehensive Phase 2 Drilling Across the Quiulacocha Tailings Facility
-
AI is transforming customer experience in EMEA; But not for everyone
-
ESET Research uncovers Gorbag, Russia-aligned threat group harvesting intelligence from Ukraine
-
Form 8.5 (EPT/RI)-Gamma Communications Plc
-
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
-
Form 8.3 - GAMMA COMMUNICATIONS PLC
-
DSV, 1180 - SHARE BUYBACK IN DSV A/S
-
Transaction in Own Shares
-
OMODA X, 5-kWh HEV Technology and Dual Intelligent Technologies Take Center Stage as Global Users Bring DRIVE TO THE NEXT VIBE to Life
-
Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc
-
Form 8.5 (EPT/RI)-Pollen Street Group Limited
-
Human Appeal Receives Canadian Parliamentary Delegation to Rare Hospital in Northwest Syria
-
Total Voting Rights
-
Lleida.net invoices 4,902 customers in the third quarter, up 44%
-
Upgrade of revenue and operating profit guidance
-
RESULT OF RIKSBANK CERTIFICATE SALE
-
Form 8.5 (EPT/RI) - Pharos Energy Plc
-
Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal
-
Peer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing Antibodies
-
Transactions in connection with share buy-back program
-
Peer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing Antibodies
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 02 11 2026] - (CGWL)
-
Resolutions of the Extraordinary General Meeting of shareholders of Nordic Fibreboard AS
-
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
-
UKey's Latest Firmware Passes CertiK Security Audit, With All Findings Remediated
-
UKey's Latest Firmware Passes CertiK Security Audit, With All Findings Remediated
-
Phrasly Launches a Free AI Image Detector as Fake Profile Photos, Listings, and News Images Become the Norm
-
AiMOGA’s Strategic AI Ecosystem Creates New Opportunities for LUXEED’s Intelligent Evolution
-
Global Licensing Group Rebrands as Brand Licensing by Informa: A Bold New Identity for a Booming Industry
-
Faraday Accelerates AI-Driven Manufacturing and Humanoid Robotics with EtherCAT-Compliant Ethernet PHY IP
-
Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion
-
AB Akola Group plans to invest EUR 52 million in its businesses in 2026/27
-
Third Quarter Report 2026
-
GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12
-
EDF: EDF announces exercise of option to redeem hybrid bonds
-
Solar A/S: No. 14 2026 Q3 EBITDA in line with expectations
-
INQ Group AB (publ) raises SEK 7 million under convertible loan facility from new US-based investment manager
-
Equinor ASA: Share buy-back – fourth tranche for 2026
-
Transaction in Own Shares
-
Progress on share buyback programme
-
AS Tallink Grupp Statistics for October 2026
-
Solar A/S: No. 13 2026 Financial calendar 2027 for Solar
-
STARTRADER Spotlights ANTHUSD Pre-IPO CFD as Anthropic Files to List on Nasdaq
-
Merck KGaA, Darmstadt, Germany, to Divest CDMO Business to Lonza
-
Merck to Divest CDMO Business to Lonza
